Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2018 Oct 3;13(4):479–487. doi: 10.1007/s11481-018-9813-6

Table 3.

History of physical and psychiatric conditions

Current use

Abstinent (n=63) Low use (n=24) Heavy use (n=24) Total (N=111)
Physical comorbidities (%)
    Any physical comorbidity 44.4 62.5 54.2 50.5
    Epilepsy or seizure disorder 6.6 4.2 0.0 4.6
    Liver disease 4.9 12.5 0.0 5.6
    Kidney disease 1.6 0.0 0.0 0.9
    Immune disorders 1.6 0.0 4.4 1.9
    Heart/cardiovascular conditions 1.6 0.0 0.0 0.9
    Asthma 11.5 16.7 21.7 14.8
    Other respiratory problems 8.2 12.5 8.7 9.3
    Diabetes 3.3 0.0 4.4 2.8
    Gastrointestinal disorders 4.8 8.3 4.4 5.5
    Chronic pain conditions 11.5 20.8 26.1 16.7
    Sexual Dysfunction 1.6 0.0 8.7 2.8
    Sexually transmitted diseases 16.4 17.4 17.4 16.8
    Sleep disorder 21.0 26.1 21.7 22.2
Psychiatric comorbidities (%)
    Any psychiatric comorbidity 55.6 54.2 50.0 54.1
    Schizophrenia 6.6 0.0 0.0 3.7
    Major depressive disorder 22.6 26.1 21.7 23.2
    Bipolar disorder 18.0 30.4 13.0 19.6
    Anxiety/PTSD/Panic disorder 41.9 30.4 39.1 38.9
    ADHD 16.1 18.2 30.4 19.6

Group comparison based on Chi-square test

*

P<0.05,

**

P<0.01